Voyager Therapeutics (NASDAQ:VYGR) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a buy rating in a report released on Saturday.

A number of other brokerages have also recently commented on VYGR. Wedbush reduced their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, October 24th. Finally, Leerink Partners initiated coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Voyager Therapeutics currently has an average rating of “Buy” and a consensus target price of $17.43.

Voyager Therapeutics Price Performance

Shares of VYGR stock opened at $6.65 on Friday. Voyager Therapeutics has a 52 week low of $5.71 and a 52 week high of $11.72. The firm has a market capitalization of $362.64 million, a PE ratio of 23.75 and a beta of 0.89. The company has a 50 day moving average price of $6.56 and a 200-day moving average price of $7.55.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The business had revenue of $29.58 million during the quarter, compared to the consensus estimate of $11.52 million. During the same period in the previous year, the company posted ($0.51) EPS. Analysts anticipate that Voyager Therapeutics will post -1.27 earnings per share for the current year.

Insider Activity at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.53% of the stock is currently owned by company insiders.

Institutional Trading of Voyager Therapeutics

A number of hedge funds have recently bought and sold shares of VYGR. Ameritas Investment Partners Inc. lifted its position in Voyager Therapeutics by 49.6% during the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after acquiring an additional 1,300 shares during the last quarter. Plato Investment Management Ltd purchased a new position in shares of Voyager Therapeutics during the 1st quarter valued at about $38,000. China Universal Asset Management Co. Ltd. raised its position in Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after acquiring an additional 4,098 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Voyager Therapeutics during the 2nd quarter worth approximately $85,000. Finally, ProShare Advisors LLC purchased a new position in shares of Voyager Therapeutics during the 1st quarter valued at approximately $101,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.